In this episode, Martin discusses a biotech company he believes faces significant regulatory risk from an upcoming FDA decision and examines the clinical and valuation factors behind his bearish outlook. He also analyzes Dell’s exposure to AI infrastructure and explains why its low-margin business model could limit the upside, before sharing his perspective on index investing, market valuations, and why he believes selective stock picking can offer different opportunities in the current environment.
Podden och tillhörande omslagsbild på den här sidan tillhör
Urban Tapes. Innehållet i podden är skapat av Urban Tapes och inte av,
eller tillsammans med, Poddtoppen.
